Gliosarcoma Clinical Trial
Official title:
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Verified date | March 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Status | Active, not recruiting |
Enrollment | 159 |
Est. completion date | March 11, 2025 |
Est. primary completion date | April 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PRIOR TO STEP 1 REGISTRATION: - No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered) - Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis - Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted - Contrast-enhanced brain MRI within 3 days after surgery - MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required - 3D pre contrast-enhanced T1 sequences are strongly suggested - Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - PRIOR TO STEP 2 REGISTRATION: - Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review - Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant - MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded. - Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization - Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011 - IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.) - Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test - History/physical examination within 28 days prior to step 2 registration - Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration - Neurologic function assessment within 28 days prior to step 2 registration - Age >= 18 years - Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration) - Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration) - Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration) - Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration) - Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration) - Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration) - Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration) - Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration) - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start - Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes Exclusion Criteria: - Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery; - Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent - Current or planned treatment with any other investigational agents for the study cancer - Definitive clinical or radiologic evidence of metastatic disease outside the brain - Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years - Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields - Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants - History of severe hypersensitivity reaction to any monoclonal antibody - History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide - On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed - Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody - History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) - Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease - Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy: - Vitiligo - Type I diabetes - Rheumatoid arthritis and other arthropathies - Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA) - Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible - Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded - Current or planned therapy with warfarin |
Country | Name | City | State |
---|---|---|---|
United States | Hawaii Cancer Care - Westridge | 'Aiea | Hawaii |
United States | Pali Momi Medical Center | 'Aiea | Hawaii |
United States | Queen's Cancer Center - Pearlridge | 'Aiea | Hawaii |
United States | The Cancer Center of Hawaii-Pali Momi | 'Aiea | Hawaii |
United States | Summa Health System - Akron Campus | Akron | Ohio |
United States | Lehigh Valley Hospital-Cedar Crest | Allentown | Pennsylvania |
United States | American Fork Hospital / Huntsman Intermountain Cancer Center | American Fork | Utah |
United States | Mary Greeley Medical Center | Ames | Iowa |
United States | McFarland Clinic - Ames | Ames | Iowa |
United States | Kaiser Permanente-Anaheim | Anaheim | California |
United States | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan |
United States | Sutter Auburn Faith Hospital | Auburn | California |
United States | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn | California |
United States | Augusta University Medical Center | Augusta | Georgia |
United States | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland |
United States | Eastern Maine Medical Center | Bangor | Maine |
United States | MaineHealth Coastal Cancer Treatment Center | Bath | Maine |
United States | UM Upper Chesapeake Medical Center | Bel Air | Maryland |
United States | Waldo County General Hospital | Belfast | Maine |
United States | Nebraska Medicine-Bellevue | Bellevue | Nebraska |
United States | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota |
United States | Central Vermont Medical Center/National Life Cancer Treatment | Berlin | Vermont |
United States | Billings Clinic Cancer Center | Billings | Montana |
United States | University of Alabama at Birmingham Cancer Center | Birmingham | Alabama |
United States | Sanford Bismarck Medical Center | Bismarck | North Dakota |
United States | Illinois CancerCare-Bloomington | Bloomington | Illinois |
United States | Saint Luke's Cancer Institute - Boise | Boise | Idaho |
United States | Bozeman Health Deaconess Hospital | Bozeman | Montana |
United States | Lafayette Family Cancer Center-EMMC | Brewer | Maine |
United States | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan |
United States | Trinity Health Medical Center - Brighton | Brighton | Michigan |
United States | Crozer-Keystone Regional Cancer Center at Broomall | Broomall | Pennsylvania |
United States | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin |
United States | University of Vermont and State Agricultural College | Burlington | Vermont |
United States | University of Vermont Medical Center | Burlington | Vermont |
United States | Fairview Ridges Hospital | Burnsville | Minnesota |
United States | Minnesota Oncology - Burnsville | Burnsville | Minnesota |
United States | Saint James Community Hospital and Cancer Treatment Center | Butte | Montana |
United States | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Idaho |
United States | Illinois CancerCare-Canton | Canton | Illinois |
United States | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan |
United States | Trinity Health Medical Center - Canton | Canton | Michigan |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | Illinois CancerCare-Carthage | Carthage | Illinois |
United States | Sandra L Maxwell Cancer Center | Cedar City | Utah |
United States | Centralia Oncology Clinic | Centralia | Illinois |
United States | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania |
United States | Atrium Health Pineville/LCI-Pineville | Charlotte | North Carolina |
United States | Carolinas Medical Center/Levine Cancer Institute | Charlotte | North Carolina |
United States | Saint Joseph Mercy Chelsea | Chelsea | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan |
United States | Northwestern University | Chicago | Illinois |
United States | University of Illinois | Chicago | Illinois |
United States | Clackamas Radiation Oncology Center | Clackamas | Oregon |
United States | Providence Cancer Institute Clackamas Clinic | Clackamas | Oregon |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Mercy Cancer Center-West Lakes | Clive | Iowa |
United States | Mission Cancer and Blood - West Des Moines | Clive | Iowa |
United States | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | Tennessee |
United States | Penrose-Saint Francis Healthcare | Colorado Springs | Colorado |
United States | Central Maryland Radiation Oncology in Howard County | Columbia | Maryland |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | Atrium Health Cabarrus/LCI-Concord | Concord | North Carolina |
United States | John Muir Medical Center-Concord | Concord | California |
United States | Mercy Hospital | Coon Rapids | Minnesota |
United States | Heartland Oncology and Hematology LLP | Council Bluffs | Iowa |
United States | Methodist Jennie Edmundson Hospital | Council Bluffs | Iowa |
United States | Greater Regional Medical Center | Creston | Iowa |
United States | Carle at The Riverfront | Danville | Illinois |
United States | Beaumont Hospital - Dearborn | Dearborn | Michigan |
United States | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Illinois |
United States | Porter Adventist Hospital | Denver | Colorado |
United States | Broadlawns Medical Center | Des Moines | Iowa |
United States | Iowa Methodist Medical Center | Des Moines | Iowa |
United States | Mercy Medical Center - Des Moines | Des Moines | Iowa |
United States | Mission Cancer and Blood - Des Moines | Des Moines | Iowa |
United States | Mission Cancer and Blood - Laurel | Des Moines | Iowa |
United States | Ascension Saint John Hospital | Detroit | Michigan |
United States | Dublin Methodist Hospital | Dublin | Ohio |
United States | Fairview Southdale Hospital | Edina | Minnesota |
United States | Carle Physician Group-Effingham | Effingham | Illinois |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | Elmhurst Memorial Hospital | Elmhurst | Illinois |
United States | Illinois CancerCare-Eureka | Eureka | Illinois |
United States | NorthShore University HealthSystem-Evanston Hospital | Evanston | Illinois |
United States | Inova Schar Cancer Institute | Fairfax | Virginia |
United States | Sanford Broadway Medical Center | Fargo | North Dakota |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Genesys Hurley Cancer Institute | Flint | Michigan |
United States | Hurley Medical Center | Flint | Michigan |
United States | Beebe South Coastal Health Campus | Frankford | Delaware |
United States | Unity Hospital | Fridley | Minnesota |
United States | Saint Luke's Cancer Institute - Fruitland | Fruitland | Idaho |
United States | Illinois CancerCare-Galesburg | Galesburg | Illinois |
United States | Western Illinois Cancer Treatment Center | Galesburg | Illinois |
United States | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois |
United States | Aurora Health Care Germantown Health Center | Germantown | Wisconsin |
United States | UM Baltimore Washington Medical Center/Tate Cancer Center | Glen Burnie | Maryland |
United States | NorthShore University HealthSystem-Glenbrook Hospital | Glenview | Illinois |
United States | Aurora Cancer Care-Grafton | Grafton | Wisconsin |
United States | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids | Michigan |
United States | Benefis Sletten Cancer Institute | Great Falls | Montana |
United States | Aurora BayCare Medical Center | Green Bay | Wisconsin |
United States | Legacy Mount Hood Medical Center | Gresham | Oregon |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Hartford Hospital | Hartford | Connecticut |
United States | NorthShore University HealthSystem-Highland Park Hospital | Highland Park | Illinois |
United States | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu | Hawaii |
United States | Hawaii Cancer Care Inc-Liliha | Honolulu | Hawaii |
United States | Island Urology | Honolulu | Hawaii |
United States | Kapiolani Medical Center for Women and Children | Honolulu | Hawaii |
United States | Queen's Cancer Cenrer - POB I | Honolulu | Hawaii |
United States | Queen's Cancer Center - Kuakini | Honolulu | Hawaii |
United States | Queen's Medical Center | Honolulu | Hawaii |
United States | Straub Clinic and Hospital | Honolulu | Hawaii |
United States | The Cancer Center of Hawaii-Liliha | Honolulu | Hawaii |
United States | University of Hawaii Cancer Center | Honolulu | Hawaii |
United States | Memorial Hermann Texas Medical Center | Houston | Texas |
United States | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis | Indiana |
United States | IU Health Methodist Hospital | Indianapolis | Indiana |
United States | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Baptist MD Anderson Cancer Center | Jacksonville | Florida |
United States | University of Wisconsin Carbone Cancer Center Johnson Creek | Johnson Creek | Wisconsin |
United States | Castle Medical Center | Kailua | Hawaii |
United States | Borgess Medical Center | Kalamazoo | Michigan |
United States | Bronson Methodist Hospital | Kalamazoo | Michigan |
United States | West Michigan Cancer Center | Kalamazoo | Michigan |
United States | Kalispell Regional Medical Center | Kalispell | Montana |
United States | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin |
United States | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois |
United States | UC San Diego Moores Cancer Center | La Jolla | California |
United States | Lancaster General Ann B Barshinger Cancer Institute | Lancaster | Pennsylvania |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Cancer Centers of Southwest Oklahoma Research | Lawton | Oklahoma |
United States | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon | New Hampshire |
United States | Beebe Medical Center | Lewes | Delaware |
United States | University of Kentucky/Markey Cancer Center | Lexington | Kentucky |
United States | Wilcox Memorial Hospital and Kauai Medical Clinic | Lihue | Hawaii |
United States | Cancer Partners of Nebraska | Lincoln | Nebraska |
United States | Cancer Partners of Nebraska - Pine Lake | Lincoln | Nebraska |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Littleton Adventist Hospital | Littleton | Colorado |
United States | Saint Barnabas Medical Center | Livingston | New Jersey |
United States | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan |
United States | Logan Regional Hospital | Logan | Utah |
United States | Loma Linda University Medical Center | Loma Linda | California |
United States | Cedars Sinai Medical Center | Los Angeles | California |
United States | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California |
United States | Illinois CancerCare-Macomb | Macomb | Illinois |
United States | University of Wisconsin Carbone Cancer Center - University Hospital | Madison | Wisconsin |
United States | Fairview Clinics and Surgery Center Maple Grove | Maple Grove | Minnesota |
United States | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota |
United States | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin |
United States | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois |
United States | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis | Tennessee |
United States | Saint Luke's Cancer Institute - Meridian | Meridian | Idaho |
United States | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin |
United States | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin |
United States | Aurora Sinai Medical Center | Milwaukee | Wisconsin |
United States | Health Partners Inc | Minneapolis | Minnesota |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin |
United States | Forbes Hospital | Monroeville | Pennsylvania |
United States | Morristown Medical Center | Morristown | New Jersey |
United States | Intermountain Medical Center | Murray | Utah |
United States | Saint Alphonsus Cancer Care Center-Nampa | Nampa | Idaho |
United States | Saint Luke's Cancer Institute - Nampa | Nampa | Idaho |
United States | Edward Hospital/Cancer Center | Naperville | Illinois |
United States | Jersey Shore Medical Center | Neptune | New Jersey |
United States | The Hospital of Central Connecticut | New Britain | Connecticut |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | Ochsner Medical Center Jefferson | New Orleans | Louisiana |
United States | Tulane University School of Medicine | New Orleans | Louisiana |
United States | Cancer Center of Western Wisconsin | New Richmond | Wisconsin |
United States | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York |
United States | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York | New York |
United States | NYP/Weill Cornell Medical Center | New York | New York |
United States | Christiana Care Health System-Christiana Hospital | Newark | Delaware |
United States | Delaware Clinical and Laboratory Physicians PA | Newark | Delaware |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Medical Oncology Hematology Consultants PA | Newark | Delaware |
United States | Providence Newberg Medical Center | Newberg | Oregon |
United States | Cancer Care Center of O'Fallon | O'Fallon | Illinois |
United States | McKay-Dee Hospital Center | Ogden | Utah |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Nebraska Medicine-Village Pointe | Omaha | Nebraska |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Kaiser Permanente-Ontario | Ontario | California |
United States | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California |
United States | AdventHealth Orlando | Orlando | Florida |
United States | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin |
United States | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | Parker Adventist Hospital | Parker | Colorado |
United States | Illinois CancerCare-Pekin | Pekin | Illinois |
United States | Capital Health Medical Center-Hopewell | Pennington | New Jersey |
United States | Illinois CancerCare-Peoria | Peoria | Illinois |
United States | Methodist Medical Center of Illinois | Peoria | Illinois |
United States | OSF Saint Francis Medical Center | Peoria | Illinois |
United States | Illinois CancerCare-Peru | Peru | Illinois |
United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | Avera Cancer Institute at Pierre | Pierre | South Dakota |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | Michigan Healthcare Professionals Pontiac | Pontiac | Michigan |
United States | Kaiser Permanente Northwest | Portland | Oregon |
United States | Legacy Good Samaritan Hospital and Medical Center | Portland | Oregon |
United States | Maine Medical Center-Bramhall Campus | Portland | Maine |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Providence Saint Vincent Medical Center | Portland | Oregon |
United States | Illinois CancerCare-Princeton | Princeton | Illinois |
United States | Utah Valley Regional Medical Center | Provo | Utah |
United States | Aurora Cancer Care-Racine | Racine | Wisconsin |
United States | Beebe Health Campus | Rehoboth Beach | Delaware |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | Riverton Hospital | Riverton | Utah |
United States | University of Rochester | Rochester | New York |
United States | Rock Hill Radiation Therapy Center | Rock Hill | South Carolina |
United States | UW Health Carbone Cancer Center Rockford | Rockford | Illinois |
United States | Penobscot Bay Medical Center | Rockport | Maine |
United States | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California |
United States | Sutter Roseville Medical Center | Roseville | California |
United States | William Beaumont Hospital-Royal Oak | Royal Oak | Michigan |
United States | Sutter Medical Center Sacramento | Sacramento | California |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Ascension Saint Mary's Hospital | Saginaw | Michigan |
United States | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan |
United States | Saint George Regional Medical Center | Saint George | Utah |
United States | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | United Hospital | Saint Paul | Minnesota |
United States | Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah |
United States | LDS Hospital | Salt Lake City | Utah |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
United States | MaineHealth Cancer Care Center of York County | Sanford | Maine |
United States | Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah | Georgia |
United States | Memorial Health University Medical Center | Savannah | Georgia |
United States | Maine Medical Center- Scarborough Campus | Scarborough | Maine |
United States | Maine Medical Partners Neurology | Scarborough | Maine |
United States | Virginia Mason Medical Center | Seattle | Washington |
United States | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin |
United States | Avera Cancer Institute | Sioux Falls | South Dakota |
United States | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | VCU Community Memorial Health Center | South Hill | Virginia |
United States | Maine Medical Partners - South Portland | South Portland | Maine |
United States | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven | Mississippi |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Southern Illinois University School of Medicine | Springfield | Illinois |
United States | Springfield Clinic | Springfield | Illinois |
United States | Lakeview Hospital | Stillwater | Minnesota |
United States | Aurora Medical Center in Summit | Summit | Wisconsin |
United States | Overlook Hospital | Summit | New Jersey |
United States | State University of New York Upstate Medical University | Syracuse | New York |
United States | Ascension Saint Joseph Hospital | Tawas City | Michigan |
United States | Lewis Hall Singletary Oncology Center | Thomasville | Georgia |
United States | Torrance Memorial Medical Center | Torrance | California |
United States | Torrance Memorial Physician Network - Cancer Care | Torrance | California |
United States | William Beaumont Hospital - Troy | Troy | Michigan |
United States | Legacy Meridian Park Hospital | Tualatin | Oregon |
United States | Saint Luke's Cancer Institute - Twin Falls | Twin Falls | Idaho |
United States | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers | Wisconsin |
United States | Carle Cancer Center | Urbana | Illinois |
United States | The Carle Foundation Hospital | Urbana | Illinois |
United States | Legacy Cancer Institute Medical Oncology and Day Treatment | Vancouver | Washington |
United States | Legacy Salmon Creek Hospital | Vancouver | Washington |
United States | John Muir Medical Center-Walnut Creek | Walnut Creek | California |
United States | Saint John Macomb-Oakland Hospital | Warren | Michigan |
United States | Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois |
United States | Illinois CancerCare - Washington | Washington | Illinois |
United States | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin |
United States | Aurora West Allis Medical Center | West Allis | Wisconsin |
United States | Saint Mary's Oncology/Hematology Associates of West Branch | West Branch | Michigan |
United States | Mercy Medical Center-West Lakes | West Des Moines | Iowa |
United States | Good Samaritan University Hospital | West Islip | New York |
United States | Reading Hospital | West Reading | Pennsylvania |
United States | Wexford Health and Wellness Pavilion | Wexford | Pennsylvania |
United States | Wheeling Hospital/Schiffler Cancer Center | Wheeling | West Virginia |
United States | University of Michigan Health - West | Wyoming | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | NRG Oncology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | OS (if the Study Discontinues in Phase II) | At the end of phase II of study | ||
Other | Tumor Biomarker Analyses | Will assess PD-L1 expression and mutational burden expression specifically. | Up to 4 years | |
Other | MGMT Protein Expression | Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. | Up to 4 years | |
Primary | Progression-free Survival (PFS) (Phase II) | Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. | From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months. | |
Primary | Overall Survival (OS) (Phase III) | Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. | From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months. | |
Secondary | PFS for the Entire Cohort (Phase II/III) | Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. | From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months. | |
Secondary | Overall Survival at 2 Years | Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. | From randomization to two years | |
Secondary | Number of Participants by Highest Grade Adverse Event Reported | Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. | From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months. | |
Secondary | Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) at Six Months (Patient Reported Outcomes) | The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score is the average of the subscale items, given that a specified minimum numbers of items were completed. | Up to 2 years | |
Secondary | Neurocognitive Function (NCF) | Up to 2 years | ||
Secondary | Selected Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Items | Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01227434 -
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Completed |
NCT00960492 -
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
|
Phase 1 | |
Completed |
NCT00525525 -
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
|
Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00165477 -
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Recruiting |
NCT04555577 -
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
|
Phase 1 | |
Active, not recruiting |
NCT03137888 -
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
|
Phase 2 | |
Suspended |
NCT03197506 -
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT01430351 -
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
|
Phase 1 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Completed |
NCT00612651 -
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
|
Phase 1 | |
Completed |
NCT03043391 -
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
|
Phase 1 |